Frederick Asare, MD
Internal Medicine · Fayetteville, NCNPI 1821195090
Payments from drug & device makers
Across 171 payments — averaging $502.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$83K
- Pfizer$457
- GSK$359
- AstraZeneca$279
- Novo Nordisk$248
- Amgen$207
- plus $1K from 23 others
What the payments were for
- Consulting fees$82,66796%
- Travel & lodging$1150%
- Food & beverage$2,7073%
- Education$4751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $83,276 |
| Pfizer | 13 | $457 |
| GSK | 19 | $359 |
| AstraZeneca | 14 | $279 |
| Novo Nordisk | 9 | $248 |
| Amgen | 7 | $207 |
| Supernus Pharmaceuticals, Inc. | 14 | $132 |
| Johnson & Johnson | 5 | $130 |
| Sanofi-aventis U.S. LLC | 7 | $115 |
| Exact Sciences | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Boehringer Ingelheim | 5 | $76 |
| Novartis | 4 | $75 |
| Amarin Pharma, Inc. | 4 | $72 |
| AbbVie | 4 | $69 |
| Lilly USA, LLC | 4 | $65 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| Eisai Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Bayer | 1 | $14 |
| Medtronic | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$138
- Repatha$125
- Ozempic$125
- NURTEC ODT$124
How this compares
$85,963 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 82 | $114,972 |
| OzempicSemaglutide | 102 | $97,975 |
| EliquisApixaban | 88 | $90,027 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $43,816 |
| JanuviaSitagliptin Phosphate | 21 | $33,601 |
| LinzessLinaclotide | 45 | $29,607 |
| FarxigaDapagliflozin Propanediol | 19 | $20,931 |
| XareltoRivaroxaban | 13 | $20,384 |
| JardianceEmpagliflozin | 12 | $12,953 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $9,576 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $9,209 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,512 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,034 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $65 | $114,97282 claims |
| Novo NordiskOzempic | $248 | $97,975102 claims |
| PfizerEliquis | $457 | $90,02788 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $359 | $57,97882 claims |
| MerckJanuvia, Janumet | $12 | $43,17837 claims |
| AstraZenecaFarxiga, Symbicort | $279 | $29,91055 claims |
| AbbVieLinzess | $69 | $29,60745 claims |
| Johnson & JohnsonXarelto | $130 | $20,38413 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $76 | $19,98726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Fayetteville
- Nitin DesaiFayetteville$6.4M
- Daniel UbaFayetteville$1.2M
- Eugene WrightFayetteville$839K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.